Read Larry Connors' blog – Short Term Trading Strategies
Alzheimer's is a degenerative fatal brain disorder caused due to build up of plaques containing a protein called beta amyloid in patients' brains. The disease results in a gradual loss of memory leading to intellectual, psychological and behavioral disorders, finally proving fatal.
Speaking at the conference, William Thies, Chief Medical & Scientific Officer at the Alzheimer's Association said that early diagnosis of the disease is essential to receive the best help and care possible.
Nerida Paterson, Senior Lecturer in the Discipline of General Practice at the University of Newcastle, Australia said that a doctor's positive attitude to the diagnosis and treatment of dementia will enable early Alzheimer's diagnosis. The attitudes of 'therapeutic nihilism' surrounding dementia" need to be overcome.
According to Paterson, "therapeutic nihilism" is a belief that there is no recognized cure or effective treatment for an illness, and therefore treatment or intervention in any form is not important.
The results of two studies about Martek Biosciences Corp.'s (MATK | Quote | Chart | News | PowerRating) DHA (docosahexaenoic acid) omega-3 derived from microalgae, which was tested to see its effect on "age related cognitive decline, were presented at the conference on July 12.
One of the trials was conducted by the Alzheimer's Disease Cooperative Study, or ADCS, supported by the National Institute on Aging, or NIA, and the second by Martek. In the NIA trial, which lasted 18 months, and was conducted in people with mild to moderate Alzheimer's, DHA omega-3 showed no evidence for benefit in the studied population.
Martek's trial, which was for six months, showed a positive result on the test of memory and learning in healthy older adults, but not in people with Alzheimer's or dementia.
DHA omega-3 is a major structural fat in the brain. Previous animal studies and epidemiology in humans suggested that DHA omega-3 fatty acid may cut the build-up of the protein linked to Alzheimer's.
A poster session highlighting the topline data of oral Alzheimer's disease drug candidate -- ELND005, developed by Elan Corp. (ELN | Quote | Chart | News | PowerRating) and Transition Therapeutics Inc. (TTHI | Quote | Chart | News | PowerRating)(TTH.TO), will be held July 13 to July 15.
Till date, there has been no cure for Alzheimer's. The FDA-approved drugs, which are currently in the market, can temporarily relieve only some symptoms of the disease like, memory loss, difficulty in communicating, impaired judgment and a loss of initiative.
Forest Laboratories Inc.s' (FRX | Quote | Chart | News | PowerRating) Namenda, Sciele Pharma Inc.'s (SCRX | Quote | Chart | News | PowerRating) Cognex, Pfizer/Eisai's Aricept, Novartis AG's (NVS | Quote | Chart | News | PowerRating) Exelon, and Janssen-Ortho Inc.'s Razadyne can alleviate the symptoms of Alzheimer's like memory deterioration. With growing unmet medical need, therapeutic opportunities for Alzheimer's drug developers are still wide open. The global Alzheimer's drug market, which was worth about $500 million in 1999 climbed to over $6 billion in 2008, according to reports.
It could be a major breakthrough in the treatment of Alzheimer's if any of the drugs under development are able to reverse or halt the disease altogether.
MATK, which has thus far hit a 52-week low of $15.36 and 52-week high of $39.60 closed Friday's regular trading session at $21.70, up 2.99% on a volume of 236,831 shares.
For comments and feedback: contact editorial@rttnews.com Copyright(c) 2009 RTTNews.com, Inc. All Rights Reserved
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
